#048 $IOVA Burn Rate and Biotech Bust - Iovance’s Meltdown Explained
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
#048 $IOVA Burn Rate and Biotech Bust - Iovance’s Meltdown Explained
-
Narrated by:
-
Written by:
About this listen
Biotech hopeful Iovance $IOVA promised a blockbuster launch of its cancer drug Amtagvi—forecasting nearly half a billion in revenue. But when reality hit, it came crashing down. In this episode of Bulls & Betrayal, we uncover how lofty projections, slow treatment rollout, and alleged internal knowledge of infrastructure issues led to a brutal 45% stock plunge. Ideal for investors, healthcare analysts, and corporate truth-seekers. Expect biotech drama, class action insights, and sharp market analysis.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
Learn more or join the case at ZLK.com
No reviews yet